Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis, more commonly known as thrush, in adults and children age 16 and older.

17 Apr 2010

Men who live further from cities more likely to have chronic health problems and higher death rates, says report

According to a new report from the Australian Institute of Health and Welfare, rural men are more prone to succumb to diseases like diabetes, some cancers like of head, neck and lip, poisonings and chronic health problems compared to those living in major cities.

14 Apr 2010

Loyola University Medical Center to offer free screenings for oral, head and neck cancer

Oral, head and neck cancers — most of which are preventable — account for approximately 3 percent of all cancer cases in the United States, according to the American Cancer Society. In 2009, more than 35,000 Americans were diagnosed with these cancers and 7,600 died.

8 Apr 2010

Johns Hopkins Kimmel Cancer Center reviews top cancer stories

Surgeon Jeremy Richmon, M.D., at Johns Hopkins is using robotic assistance to cut away tumors of the tongue and tonsils. Conventional surgery leaves disfiguring neck and jaw scars, but the robotic procedure leaves no scar except for inside the mouth, and he says, patients retain good function of speech and swallowing.

5 Apr 2010

Detroit cancer center to conduct free oral, head and neck cancer screenings

On Friday, April 16, from 2 - 5 p.m., the Barbara Ann Karmanos Cancer Center in Detroit will be conducting free oral, head and neck cancer screenings in conjunction with National Oral Head and Neck Cancer Awareness Week (April 12 – 18.) Some of the symptoms of oral cancer go unnoticed. A simple 10-minute screening exam can determine if there are problems and can help diagnose this disease in its early stage.

3 Apr 2010

Identification and elimination of cancer stem cells

A new field of cancer research could explain why some cancers that appear to have been cured can rear their ugly head or spread to other organs.

3 Apr 2010

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.

3 Apr 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

Prevalence of head and neck cancer linked to human papillomavirus

Rates of oropharangeal cancer have increased by around 50 per cent in the last 20 years, according to a report in the British Medical Journal.

31 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

Inflamed tissues linked to increased production of protein involved in pain signaling

Using a novel animal model to study craniofacial pain, researchers at Oregon Health & Science University's School of Dentistry have discovered that when tissues are inflamed, the nerve cells carrying pain information from the head to the brain produce in large quantities a protein involved in pain signaling.

26 Mar 2010

New technique to deliver cancer treatments directly to certain tumours

Research conducted and patented by Dr Mark Howard at the University of Kent's School of Biosciences has led to the development of a new technique that will deliver cancer treatments directly to certain tumours.

26 Mar 2010

JCOM receives approval from KFDA to commercialize MuGard in Korea

ACCESS PHARMACEUTICALS, INC. announced that JCOM Co., Ltd., its Korean licensee for both MuGard™ and ProLindac™, has received approval from the Korean Food and Drug Administration of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis.

26 Mar 2010

UVA Health System offers Gamma Knife eXtend system to treat patients with head and neck cancer

A powerful new tool available at the University of Virginia Health System offers treatment to patients with some of the most challenging cancers of the head and neck.

16 Mar 2010

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

The Human Papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer, but is also associated with several other types of cancer.

12 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

TNFerade's suppression of cancer metastases: Mechanisms revealed

GenVec, Inc. announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system.

4 Mar 2010

Researchers develop sensitive measuring system for cGVHD

Researchers from The University of Texas M. D. Anderson Cancer Center have developed a new assessment tool to measure the severity of symptoms that can complicate stem cell transplantation. The tool assesses symptoms resulting from chronic graft-versus-host disease (cGVHD), and was presented with supporting research at the 2010 Bone and Marrow Transplant Tandem Meeting.

2 Mar 2010

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

The maximal standardized uptake value (called SUVmax) measured from FDG PET readings taken from the primary tumor in head and neck squamous cell carcinoma patients before treatment is a strong predictor of disease-specific survival, overall survival and disease-free survival, while pretreatment SUVmax for lymphodenopathy is strongly associated with distant metastasis, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

1 Mar 2010

Head and Neck Cancer News and Research

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Men who live further from cities more likely to have chronic health problems and higher death rates, says report

Loyola University Medical Center to offer free screenings for oral, head and neck cancer

Johns Hopkins Kimmel Cancer Center reviews top cancer stories

Detroit cancer center to conduct free oral, head and neck cancer screenings

Identification and elimination of cancer stem cells

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Prevalence of head and neck cancer linked to human papillomavirus

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Inflamed tissues linked to increased production of protein involved in pain signaling

New technique to deliver cancer treatments directly to certain tumours

JCOM receives approval from KFDA to commercialize MuGard in Korea

UVA Health System offers Gamma Knife eXtend system to treat patients with head and neck cancer

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

TNFerade's suppression of cancer metastases: Mechanisms revealed

Researchers develop sensitive measuring system for cGVHD

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News